Last updated: 16 September 2022 at 7:36pm EST

Ventures Fund V General Par... Net Worth




The estimated Net Worth of Ventures Fund V General Par... is at least $67.8 Mille dollars as of 15 September 2022. Ventures Par owns over 933,333 units of Codiak BioSciences stock worth over $67,768 and over the last 4 years Ventures sold CDAK stock worth over $0.

Ventures Par CDAK stock SEC Form 4 insiders trading

Ventures has made over 2 trades of the Codiak BioSciences stock since 2020, according to the Form 4 filled with the SEC. Most recently Ventures bought 933,333 units of CDAK stock worth $53,200 on 15 September 2022.

The largest trade Ventures's ever made was buying 933,333 units of Codiak BioSciences stock on 15 September 2022 worth over $53,200. On average, Ventures trades about 549,167 units every 350 days since 2020. As of 15 September 2022 Ventures still owns at least 1,188,920 units of Codiak BioSciences stock.

You can see the complete history of Ventures Par stock trades at the bottom of the page.



Insiders trading at Codiak BioSciences

Over the last 4 years, insiders at Codiak BioSciences have traded over $15,220 worth of Codiak BioSciences stock and bought 11,821,475 units worth $20,798,957 . The most active insiders traders include Steven Gillis, Venture Fund Viii, L.P.Arch... e Permanent Fund Corp Alaska. On average, Codiak BioSciences executives and independent directors trade stock every 25 days with the average trade being worth of $19,158. The most recent stock trade was executed by Yalonda Howze on 30 March 2023, trading 1,628 units of CDAK stock currently worth $326.



What does Codiak BioSciences do?

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.



What does Codiak BioSciences's logo look like?

Codiak BioSciences, Inc. logo

Complete history of Ventures Par stock trades at Codiak BioSciences

Data
#
Ditta
Persona
Trans.
Transazione
Azioni Prezzo per azione Prezzo totale Azioni dopo Fonte
15 Sep 2022 Ventures Fund V General Par...
Acquistare 933,333 $1.05 $980,000
15 Sep 2022
1,188,920
16 Oct 2020 Ventures Fund V General Par...
Acquistare 165,000 $15.00 $2,475,000
16 Oct 2020
1,143,177


Codiak BioSciences executives and stock owners

Codiak BioSciences executives and other stock owners filed with the SEC include: